Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms

Turkish journal of haematology : official journal of Turkish Society of Haematology - 31 Aug 2023

Yönal-Hindilerden İpek, Şahin Ezgi, Hindilerden Fehmi, Dağlar-Aday Aynur, Nalçacı Meliha

Abstract excerpt

Objective: The impact of JAK2V617F allele burden on clinical course in Philadelphia-negative (Ph-negative) myeloproliferative neoplasms (MPNs) is not clear. We analyzed the clinical impact of JAK2V617F allele burden in a relatively large series of patients with Ph-negative MPNs and long-term follow-up. Materials and Methods: A total of 228 patients with Ph-negative MPNs, including 118 with essential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Splenomegaly

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 37584526
DOI: 10.4274/tjh.galenos.2023.2023.0169
PMCID: PMC10476250

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative NeoplasmsPMID 37584526Read ↗

Study on the Clinical Significance of JAK2V617F Allele Burden in Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.Semantic proximity Read ↗

The impact of JAK2V617F mutation on Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging DataSemantic proximity Read ↗

High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.Semantic proximity Read ↗

The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.Semantic proximity Read ↗

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.Semantic proximity Read ↗

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.Semantic proximity Read ↗

JAK2 V617F Mutational Burden and Clinical Findings Relationship in Myeloproliferative NeoplasmsSemantic proximity Read ↗

Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.Semantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

JAK2V617F allele burden in patients with myeloproliferative neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.